Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Precision Health Acceleration: DNAnexus and Ovation Collaborate to Propel Drug Discovery and Facilitate Scientific Breakthroughs

NextEdge Admin

19 Dec 2023

2 min 23 sec

DNAnexus, Inc. and Ovation have announced a collaboration to streamline large-scale omics data analysis, initially focusing on Ovation’s inflammatory bowel disease omics data. This dataset includes whole genome sequencing and whole transcriptome sequencing linked to longitudinal clinical data. Ovation, an omics data company committed to advancing precision medicine, draws from a biobank of over 1.6 million consented samples collected from CLIA-certified clinical diagnostic labs across diverse populations. DNAnexus’ Precision Health Data Cloud, a secure and scalable platform, will be utilized to manage, analyze, and collaborate on this complex multimodal data.

The collaboration aims to enhance therapeutic biomarker and target discovery in areas like immunology, oncology, and cardiometabolic therapeutics. Ovation’s CEO, Curt Medeiros, emphasizes the importance of managing and interpreting omics data, highlighting DNAnexus’ proven track record in this field.

DNAnexus, with over 40,000 registered users across 48 countries, manages and supports over 80 petabytes of clinical genomic, proteomic, and multi-omic datasets for collaborations with pharmaceutical, academic, and government organizations. Ovation’s extensive biobank, combined with DNAnexus’ platform, is anticipated to provide rapid access to large cohorts, facilitating disease-specific omics data analysis at scale. Thomas Laur, CEO at DNAnexus, anticipates that this collaboration will deliver richer insights, accelerating scientific breakthroughs and enhancing patient care. Ovation’s focus on providing life sciences R&D teams with high-quality omics data linked to longitudinal clinical data aims to increase the probability of success in drug discovery by identifying and validating biomarkers and therapeutic targets.